


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) Compounds of the formula I



in which

- D denotes aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms which is unsubstituted or mono- or polysubstituted by Hal, A, OR<sup>2</sup>, N(R<sup>2</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, COOR<sup>2</sup> or CON(R<sup>2</sup>)<sub>2</sub>,
- X denotes -C=O or C(R<sup>3</sup>)<sub>2</sub>,
- W denotes -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-,
- R<sup>1</sup> denotes H or A, which may be substituted by OR<sup>3</sup>, S(O)<sub>n</sub>R<sup>3</sup>, N(R<sup>3</sup>)<sub>2</sub>, CN, COOR<sup>3</sup>, CON(R<sup>3</sup>)<sub>2</sub>, OCON(R<sup>3</sup>)<sub>2</sub>, N(R<sup>3</sup>)COOR<sup>3</sup>, N(R<sup>3</sup>)CON(R<sup>3</sup>)<sub>2</sub>, N(R<sup>3</sup>)SO<sub>2</sub>R<sup>3</sup>, SO<sub>2</sub>N(R<sup>3</sup>)<sub>2</sub> or -C≡C-,
- R<sup>2</sup> denotes H, A, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-Ar', -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-Het', -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-cycloalkyl, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-N(R<sup>3</sup>)<sub>2</sub> or -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-OR<sup>3</sup>,
- R<sup>3</sup> denotes H or A,
- Y denotes alkylene, cycloalkylene, Het-diyl or Ar-diyl,
- T denotes a mono- or bicyclic saturated, unsaturated or aromatic carbo- or heterocycle having 0 to 4 N, O and/or S atoms which is mono- or disubstituted by =O, =S, =NR<sup>2</sup>, =N-CN, =N-NO<sub>2</sub>, =NOR<sup>2</sup>, =NCOR<sup>2</sup>, =NCOOR<sup>2</sup>, =NOCOR<sup>2</sup> and may furthermore be mono-, di- or trisubstituted by R<sup>2</sup>, Hal, A, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-Ar, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-Het, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-cycloalkyl, OR<sup>2</sup>, N(R<sup>2</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, COOR<sup>2</sup>, CON(R<sup>2</sup>)<sub>2</sub>, NR<sup>2</sup>COA, NR<sup>2</sup>CON(R<sup>2</sup>)<sub>2</sub>, NR<sup>2</sup>SO<sub>2</sub>A, COR<sup>2</sup>, SO<sub>2</sub>NR<sup>2</sup> and/or S(O)<sub>n</sub>A,
- A denotes unbranched or branched alkyl having 1-10 C atoms, in which one or two CH<sub>2</sub> groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or also 1-7 H atoms may be replaced by F,

Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR<sup>2</sup>, N(R<sup>2</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, COOR<sup>2</sup>, CON(R<sup>2</sup>)<sub>2</sub>, NR<sup>2</sup>COA, NR<sup>2</sup>CON(R<sup>2</sup>)<sub>2</sub>, NR<sup>2</sup>SO<sub>2</sub>A, COR<sup>2</sup>, SO<sub>2</sub>N(R<sup>2</sup>)<sub>2</sub>, S(O)<sub>n</sub>A, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-COOR<sup>2</sup> or -O-[C(R<sup>3</sup>)<sub>2</sub>]<sub>o</sub>-COOR<sup>2</sup>,

Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR<sup>3</sup>, N(R<sup>3</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, COOR<sup>3</sup>, CON(R<sup>3</sup>)<sub>2</sub>, NR<sup>3</sup>COA, NR<sup>3</sup>CON(R<sup>3</sup>)<sub>2</sub>, NR<sup>3</sup>SO<sub>2</sub>A, COR<sup>3</sup>, SO<sub>2</sub>N(R<sup>3</sup>)<sub>2</sub>, S(O)<sub>n</sub>A, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-COOR<sup>3</sup> or -O-[C(R<sup>3</sup>)<sub>2</sub>]<sub>o</sub>-COOR<sup>3</sup>,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, =S, =N(R<sup>2</sup>)<sub>2</sub>, Hal, A, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-Ar, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-Het', -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-cycloalkyl, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-OR<sup>2</sup>, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-N(R<sup>3</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-COOR<sup>2</sup>, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-CON(R<sup>2</sup>)<sub>2</sub>, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-NR<sup>2</sup>COA, NR<sup>2</sup>CON(R<sup>2</sup>)<sub>2</sub>, -[C(R<sup>3</sup>)<sub>2</sub>]<sub>n</sub>-NR<sup>2</sup>SO<sub>2</sub>A, COR<sup>2</sup>, SO<sub>2</sub>NR<sup>2</sup> and/or S(O)<sub>n</sub>A,

Het' denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by carbonyl oxygen, =S, =N(R<sup>3</sup>)<sub>2</sub>, Hal, A, OR<sup>3</sup>, N(R<sup>3</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, COOR<sup>3</sup>, CON(R<sup>3</sup>)<sub>2</sub>, NR<sup>3</sup>COA, NR<sup>3</sup>CON(R<sup>3</sup>)<sub>2</sub>, NR<sup>3</sup>SO<sub>2</sub>A, COR<sup>3</sup>, SO<sub>2</sub>NR<sup>3</sup> and/or S(O)<sub>n</sub>A,

Hal denotes F, Cl, Br or I,

m denotes 1 or 2,

n denotes 0, 1 or 2,

o denotes 1, 2 or 3,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

2. (Original) Compounds according to Claim 1,  
in which

D denotes an aromatic five-ring heterocycle having 1 to 2 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

3. (Currently Amended) Compounds according to Claim 1 ~~or 2~~,  
in which

D denotes a thienyl ring which is mono- or disubstituted by Hal, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

4. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-3~~ ,

in which

R<sup>2</sup> denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

5. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-4~~,

in which

R<sup>1</sup> denotes H or A, which may be substituted by OR<sup>3</sup>, CON(R<sup>3</sup>)<sub>2</sub>, N(R<sup>3</sup>)<sub>2</sub>, S(O)<sub>n</sub>R<sup>3</sup>, COOR<sup>3</sup>, OCON(R<sup>3</sup>)<sub>2</sub>, N(R<sup>3</sup>)COOR<sup>3</sup> or -C≡C-, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

6. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-5~~,

in which

X denotes -C=O,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

7. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-6~~,

in which

W is absent,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

8. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-7~~,

in which

Y denotes Ar-diyl,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

9. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-8~~,

in which

T denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N and/or O atoms which is mono- or disubstituted by =O, =S, =NR<sup>2</sup>, =N-CN, =N-NO<sub>2</sub>, =NOR<sup>2</sup>, =NCOR<sup>2</sup>, =NCOOR<sup>2</sup> or =NOCOR<sup>2</sup> and may furthermore be mono- or disubstituted by Hal or A,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

10. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-9~~,

in which

T denotes a mono- or bicyclic saturated or unsaturated heterocycle having 1 to 2 N and/or O atoms which is mono- or disubstituted by =O, =S or =NH,  
and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

11. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-10~~,

in which

T denotes piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo[2.2.2]octan-2-yl, each of which is mono- or disubstituted by =O or =NH,  
and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

12. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-11~~,

in which

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by Hal, A, OA, SO<sub>2</sub>A, COOR<sup>2</sup>, SO<sub>2</sub>NH<sub>2</sub> or CN,  
and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

13. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-12~~,

in which

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by A and/or Hal,  
and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

14. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-13,~~

in which

D denotes aromatic five-ring heterocycle having 1 to 2 N, O and/or S atoms which is unsubstituted or mono- or disubstituted by Hal,

R<sup>1</sup> denotes H or A, which may be substituted by OR<sup>3</sup>, CON(R<sup>3</sup>)<sub>2</sub>, N(R<sup>3</sup>)<sub>2</sub>, S(O)<sub>n</sub>R<sup>3</sup>, COOR<sup>3</sup>, OCON(R<sup>3</sup>)<sub>2</sub>, N(R<sup>3</sup>)COOR<sup>3</sup> or -C≡C-,

R<sup>2</sup> denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

X denotes -C=O or CH<sub>2</sub>,

W is absent,

Y denotes Ar-diyl,

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by A and/or Hal,

T denotes a mono- or bicyclic saturated or unsaturated heterocycle having 1 to 2 N and/or O atoms which is mono- or disubstituted by =O, =S or =NH,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

15. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-14,~~

in which

D denotes thienyl, thiazolyl or furyl, each of which is mono- or disubstituted by Hal,

R<sup>1</sup> denotes H or A, which may be substituted by OR<sup>3</sup>, CON(R<sup>3</sup>)<sub>2</sub>, N(R<sup>3</sup>)<sub>2</sub>, S(O)<sub>n</sub>R<sup>3</sup>, COOR<sup>3</sup>, OCON(R<sup>3</sup>)<sub>2</sub>, N(R<sup>3</sup>)COOR<sup>3</sup> or -C≡C-,

R<sup>2</sup> denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

X denotes -C=O or CH<sub>2</sub>,

W is absent,

Y denotes Ar-diyl,

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by A and/or Hal,

T denotes piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo[2.2.2]octan-2-yl, each of which is mono- or disubstituted by =O or =NH,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

16. (Currently Amended) Compounds according to claim 1 ~~one or more of Claims 1-15~~,

in which

D denotes thienyl or phenyl, each of which is mono- or disubstituted by Hal,

R<sup>1</sup> denotes H or A, which may be substituted by OR<sup>3</sup>, CON(R<sup>3</sup>)<sub>2</sub>, N(R<sup>3</sup>)<sub>2</sub>, S(O)<sub>n</sub>R<sup>3</sup>, COOR<sup>3</sup>, OCON(R<sup>3</sup>)<sub>2</sub>, N(R<sup>3</sup>)COOR<sup>3</sup> or -C≡C-,

R<sup>2</sup> denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

R<sup>3</sup> denotes H or alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

X denotes -C=O or CH<sub>2</sub>,

W is absent or denotes CH<sub>2</sub>,

Y denotes Ar-diyl,

A denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, in which one or two CH<sub>2</sub> groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or also 1-7 H atoms may be replaced by F,

Ar denotes phenyl which is unsubstituted or mono- or disubstituted by A and/or Hal,

T denotes piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo[2.2.2]octan-2-yl, each of which is mono- or disubstituted by =O or =NH,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof,

including mixtures thereof in all ratios.

17. (Original) Compounds according to Claim 1, selected from the group

(S)-2-([(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-iminopiperidin-1-yl)phenyl]-4-methylvaleramide,

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-iminopiperidin-1-yl)phenyl]-4-methylvaleramide,

2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(2-oxopiperidin-1-yl)phenyl]acetamide,

3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(2-oxopiperidin-1-yl)phenyl]propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methylbutyramide,



(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]-3-aminocarbonylpropionamide,

(R)-2-[(4-chlorophenylcarbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(4-chlorophenylcarbonyl)amino]-*N*-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]-4-methylvaleramide,

2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]-3-(*N,N*-dimethylamino)propionamide,

(R)-2-[(5-bromothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]-4-methylvaleramide,

2-[(5-chlorothiophene-2-methyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methylsulfanylpropionamide,

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxopiperidin-1-yl)benzyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methylbutyramide,

3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]propionamide,

3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]propionamide,

3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-

yl)phenyl]propionamide,

2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]acetamide,

2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)-phenyl]acetamide,

2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]acetamide,

3-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-2-butylpropionamide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]propionamide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]valeramide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methylsulfanylpropionamide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]propionamide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methylsulfanylbutyramide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]butyramide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-ethynylpropionamide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-ethynylpropionamide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]propionamide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-methylsulfanylbutyramide,

(*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-(*tert*-butyloxycarbonyl)propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-vinylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-vinylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(*tert*-butyloxycarbonyl)propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-methoxybutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-methoxybutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-4-methylvaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-(*tert*-butyloxycarbonyl)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-(*tert*-butyloxycarbonyl)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxopiperidin-1-yl)phenyl]-4-(*tert*-butyloxycarbonyl)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-(*tert*-butyloxycarbonylamino)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-4-(*tert*-butyloxycarbonylamino)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-5-(*tert*-butyloxycarbonylamino)valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-5-(*tert*-butyloxycarbonylamino)valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-3-(*tert*-butoxycarbonylamino)propionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(*tert*-butoxycarbonylamino)propionamide,

(R)-3-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]butyramide,

(R)-3-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-5-methyladipamide,

(S)-3-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-5-methyladipamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methoxypropionamide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[4-(3-oxomorpholin-4-yl)phenyl]-3-methoxybutyramide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methoxybutyramide,

(S)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-trifluoromethyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-chloro-4-(2-azabicyclo[2.2.2]octan-2-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-trifluoromethoxy-4-(2-azabicyclo[2.2.2]octan-2-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-chloro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]-3-allylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]-3-propoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]-3-ethoxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]-3-(2-methoxyethoxy)propionamide,

(2*R*,3*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-ethoxybutyramide,

(2*R*,3*R*)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(2-methoxyethoxy)butyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-methylsulfonylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methylsulfonylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methylsulfonylpropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-methylsulfonylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]-3-methylsulfonylbutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-methylsulfonylbutyramide,

(R)-2-[(5-chlorothiophen-2-ylmethyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]valeramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-carboxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]-3-carboxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-carboxybutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]-4-carboxybutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-4-aminobutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]-4-aminobutyramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-5-aminovaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]-5-aminovaleramide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-aminopropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxo-morpholin-4-yl)phenyl]-3-aminopropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-hydroxypropionamide,

(R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-4-(3-oxomorpholin-4-yl)phenyl]-3-hydroxypropionamide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-hydroxybutyramide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[4-(3-oxomorpholin-4-yl)phenyl]-3-aminocarbonyloxybutyramide,

(2R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-aminocarbonyloxypropionamide,

(2R,3R)-2-[(5-chlorothiophene-2-carbonyl)amino]-*N*-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-aminocarbonyloxybutyramide,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.


18. (Currently Amended) Process for the preparation of compounds of the formula I according to claim 1 ~~Claims 1-17~~ and pharmaceutically usable derivatives, solvates and stereoisomers thereof, characterised in that
- a) a compound of the formula II



in which

W, Y and T have the meanings indicated in Claim 1,

is reacted with a compound of the formula III



in which


L denotes Cl, Br, I or a free or reactively functionally modified OH group, and

R<sup>1</sup>, m, X and D have the meanings indicated in Claim 1,

or

- b) for the preparation of compounds of the formula I,  
in which X denotes -C=O,

a compound of the formula IV



in which  $\text{R}^1$ ,  $m$ ,  $\text{W}$ ,  $\text{Y}$  and  $\text{T}$  have the meanings indicated in Claim 1,

is reacted with a compound of the formula V



in which

$\text{L}$  denotes  $\text{Cl}$ ,  $\text{Br}$ ,  $\text{I}$  or a free or reactively functionally modified  $\text{OH}$  group, and


$\text{D}$  has the meaning indicated in Claim 1,

or

c) for the preparation of compounds of the formula I

in which  $\text{X}$  denotes  $\text{CH}_2$ ,

a compound of the formula IV



in which  $\text{R}^1$ ,  $m$ ,  $\text{W}$ ,  $\text{Y}$  and  $\text{T}$  have the meanings indicated in Claim 1,

is reacted with a compound of the formula VI



in which

$\text{D}$  has the meaning indicated in Claim 1,



in a reductive amination,

and/or

a base or acid of the formula I is converted into one of its salts.

19. (Currently Amended) Compounds of the formula I according to claim 1 ~~one or more of Claims 1 to 17~~ as inhibitors of coagulation factor Xa.
20. (Currently Amended) Compounds of the formula I according to claim 1 ~~one or more of Claims 1 to 17~~ as inhibitors of coagulation factor VIIa.
21. (Currently Amended) Medicaments comprising at least one compound of the formula I according to claim 1 ~~one or more of Claims 1 to 17~~ and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.
22. (Currently Amended) Medicaments comprising at least one compound of the formula I according to claim 1 ~~one or more of Claims 1 to 17~~ and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
23. (Currently Amended) Use of compounds according to claim 1 ~~one or more of Claims 1 to 17~~ and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases.
24. (Currently Amended) Set (kit) consisting of separate packs of
  - (a) an effective amount of a compound of the formula I according

to claim 1 ~~one or more of Claims 1 to 17~~ and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,

and

(b) an effective amount of a further medicament active ingredient.